Enhanced passive safety surveillance of high-dose and standard-dose quadrivalent inactivated split-virion influenza vaccines in Germany and Finland during the influenza season 2021/22

Sonja Gandhi-Banga, Sophie Wague, Anju Shrestha, Olga Syrkina, Oxana Talanova, Markku Nissilä, Karl Stuff, Céline Monfredo, Sonja Gandhi-Banga, Sophie Wague, Anju Shrestha, Olga Syrkina, Oxana Talanova, Markku Nissilä, Karl Stuff, Céline Monfredo

Abstract

Background: Enhanced passive safety surveillance (EPSS) was conducted for quadrivalent inactivated split-virion influenza vaccines (IIV4) in Germany (high dose [HD], aged ≥60 years) and in Finland (standard dose [SD], aged ≥6 months) at the beginning of the northern hemisphere 2021/22 influenza season. The primary objective was to assess adverse drug reactions (ADRs) occurring ≤7 days post-vaccination.

Methods: Vaccinees were issued vaccination cards (VC) and were encouraged to report ADRs via an electronic data collection system or by telephone. ADRs were assessed by frequency, time to onset, intensity and by age group. The vaccinee reporting rate (RR) was calculated as the number of vaccinees reporting ≥1 ADR divided by total vaccinees. Reactogenicity was compared with previous experiences with each vaccine.

Results: Among 903 HD-IIV4 vaccinees in Germany, 17 reported ≥1 ADR within ≤7 days post-vaccination: RR, 1.88% (95% CI: 1.10, 3.00). Time to onset was known for 53/65 ADRs, all of which occurred ≤7 days post-vaccination. In Germany, seven ADRs were reported that were not listed previously. Among the 1000 SD-IIV4 vaccinees in Finland, 49 reported ≥1 ADR within ≤7 days post-vaccination: RR, 4.90% (95% CI: 3.65, 6.43). Time to onset was known for 126/134 ADRs, of which 125 occurred ≤7 days post-vaccination. In Finland, 21 ADRs were reported that were not listed previously. No ADRs reported during follow-up were serious.

Conclusions: The EPSS for HD-IIV4 and for SD-IIV4 in the 2021/22 influenza season did not suggest any clinically relevant changes in safety beyond what is known/expected for IIV4s.

Keywords: Efluelda; IIV4; Vaxigrip Tetra; influenza vaccine; quadrivalent split-virion inactivated influenza vaccine; seasonal influenza.

Conflict of interest statement

SGB, SW, CM, OS and AS are employees of Sanofi and may hold shares and/or stock options in the company.

© 2022 Sanofi. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.

References

    1. Pharmacovigilance risk assessment committee (PRAC) EMA . Interim guidance on enhanced safety surveillance for seasonal influenza vaccines in the EU 2014 [cited 2014. April 10]; Available from:
    1. Alicino C, Merlano C, Zappettini S, et al. Routine surveillance of adverse events following immunization as an important tool to monitor vaccine safety. Hum Vaccin Immunother. 2015;11(1):91‐94. doi:10.4161/hv.34360 [published Online First: 2014/12/09].
    1. Bricout H, Chabanon AL, Souverain A, Sadorge C, Vesikari T, Caroe TD. Passive enhanced safety surveillance for Vaxigrip and Intanza 15 μg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16. Euro Surveill. 2017;22(18):30527. doi:10.2807/1560-7917.es.2017.22.18.30527 [published Online First: 2017/05/13].
    1. Chabanon AL, Wague S, Moureau A, Nissila M, Serradell L. Enhanced passive safety surveillance of the quadrivalent inactivated split‐virion influenza vaccine (IIV4) in Finland during the 2019/20 influenza season. BMC Public Health. 2021;21(1):358. doi:10.1186/s12889-021-10378-8 [published Online First: 2021/02/17].
    1. Clothier HJ, Crawford NW, Kempe A, Buttery JP. Surveillance of adverse events following immunisation: the model of SAEFVIC, Victoria. Commun Dis Intell Q Rep. 2011;35(4):294‐298. [published Online First: 2012/05/26].
    1. Gandhi‐Banga S, Chabanon AL, Eymin C, Caroe T, Butler K, Moureau A. Enhanced passive safety surveillance of three marketed influenza vaccines in the UK and the Republic of Ireland during the 2017/18 season. Hum Vaccin Immunother. 2019;15(9):2154‐2158. doi:10.1080/21645515.2019.1581538 [published Online First: 2019/03/22].
    1. Bardenheier BH, Duderstadt SK, Engler RJ, McNeil MM. Adverse events following pandemic influenza a (H1N1) 2009 monovalent and seasonal influenza vaccinations during the 2009‐2010 season in the active component U.S. military and civilians aged 17‐44years reported to the vaccine adverse event reporting system. Vaccine. 2016;34(37):4406‐4414. doi:10.1016/j.vaccine.2016.07.019 [published Online First: 2016/07/28].
    1. Efluelda . Summary of Product Characteristics. Sanofi Pasteur, 2021.
    1. Lee JKH, Lam GKL, Shin T, Samson SI, Greenberg DP, Chit A. Efficacy and effectiveness of high‐dose influenza vaccine in older adults by circulating strain and antigenic match: an updated systematic review and meta‐analysis. Vaccine. 2021;39:A24‐A35. doi:10.1016/j.vaccine.2020.09.004
    1. Chang LJ, Meng Y, Janosczyk H, Landolfi V, Talbot HK, QHD00013 Study Group . Safety and immunogenicity of high‐dose quadrivalent influenza vaccine in adults ≥65 years of age: a phase 3 randomized clinical trial. Vaccine. 2019;37(39):5825‐5834. doi:10.1016/j.vaccine.2019.08.016 [published Online First: 2019/08/23].
    1. Vaxigrip Tetra . Summary of Product Characteristics. Sanofi Pasteur, 2022.
    1. Pepin S, Dupuy M, Borja‐Tabora CFC, et al. Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6‐35 months: a multi‐season randomised placebo‐controlled trial in the northern and southern hemispheres. Vaccine. 2019;37(13):1876‐1884. doi:10.1016/j.vaccine.2018.11.074 [published Online First: 2018/12/19].
    1. Syrkina O, Inamdar A, Wague S, et al. Enhanced passive safety surveillance of a quadrivalent inactivated split virion influenza vaccine in Finland during the influenza season 2020/21. BMC Public Health. 2022;22(1):1506. doi:10.1186/s12889-022-13898-z
    1. German Standing Committee on Vaccinations . Vaccination recommendations by STIKO. Available at:
    1. Finish Institute for health and Welfare . Influenza vaccine. Available at:
    1. World Health Organization . WHO Regional Office for Europe recommendations on influenza vaccination for the 2021/2022 season during the ongoing COVID‐19 pandemic. 2021. Available at:
    1. Serradell L, Wagué S, Moureau A, Nissilä M, Chabanon AL. Enhanced passive safety surveillance of a trivalent and a quadrivalent influenza vaccine in Denmark and Finland during the 2018/2019 season. Hum Vaccin Immunother. 2021;17(4):1205‐1210. doi:10.1080/21645515.2020.1804247 [published Online First: 2020/09/24].
    1. Chabanon AL, Bricout H, Ballandras C, Souverain A, Caroe TD, Butler KM. Report from enhanced safety surveillance of two influenza vaccines (Vaxigrip and Intanza 15 mug) in two European countries during influenza season 2016/17 and comparison with 2015/16 season. Hum Vaccin Immunother. 2018;14(2):378‐385. doi:10.1080/21645515.2017.1405882 [published Online First: 2017/11/18].
    1. Mahajan D, Roomiani I, Gold MS, Lawrence GL, McIntyre P, Menzies RI. Annual report: surveillance of adverse events following immunisation in Australia, 2009. Commun Dis Intell Q Rep. 2010;34(3):259‐276.
    1. Vellozzi C, Burwen DR, Dobardzic A, Ball R, Walton K, Haber P. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vaccine. 2009;27(15):2114‐2120. doi:10.1016/j.vaccine.2009.01.125 [published Online First: 2009/04/10].
    1. Vellozzi C, Broder KR, Haber P, et al. Adverse events following influenza a (H1N1) 2009 monovalent vaccines reported to the vaccine adverse event reporting system, United States, October 1, 2009‐January 31, 2010. Vaccine. 2010;28(45):7248‐7255. doi:10.1016/j.vaccine.2010.09.021 [published Online First: 2010/09/21].

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel